Genome-scale high-throughput sequencing enables the detection of unprecedented numbers of sequence variants. Variant filtering and interpretation are facilitated by mutation databases, in silico tools, and population-based reference datasets such as ExAC/gnomAD, while variants are classified using the ACMG/AMP guidelines. These methods, however, pose clinically relevant challenges. We queried the gnomAD dataset for (likely) pathogenic variants in genes causing autosomal-dominant disorders. Furthermore, focusing on the fibrillinopathies Marfan syndrome (MFS) and congenital contractural arachnodactyly (CCA), we screened 500 genomes of our patients for cooccurring variants in FBN1 and FBN2. In gnomAD, we detected 2653 (likely) pathogenic variants in 253 genes associated with autosomal-dominant disorders, enabling the estimation of variant-filtering thresholds and disease predisposition/prevalence rates. In our database, we discovered two families with hitherto unreported co-occurrence of FBN1/FBN2 variants causing phenotypes with mixed or modified MFS/CCA clinical features. We show that (likely) pathogenic gnomAD variants may be more frequent than expected and are challenging to classify according to the ACMG/AMP guidelines as well as that fibrillinopathies are likely underdiagnosed and may co-occur. Consequently, selection of appropriate frequency cutoffs, recognition of digenic variants, and variant classification represent considerable challenges in variant interpretation. Neglecting these challenges may lead to incomplete or missed diagnoses. K E Y W O R D S congenital contractural arachnodactyly, digenic variants, genome sequencing, Marfan syndrome, variant interpretation
| INTRODUCTION
Current high-throughput sequencing (HTS) technologies such as whole-exome (WES) and whole-genome sequencing (WGS) enable the detection of ten thousands and millions of sequence variants, respectively. For Mendelian disorders, the identification of typically one or two disease-causing sequence variants represents a bottleneck in the filtering and interpretation of the large number of sequence variants detected by HTS. As sequence variants causing Mendelian disorders are expected to be rare, 1 filtering for sequence variants absent or infrequent in population-based reference datasets is one of the main Arash Najafi and Sylvan M. Caspar contributed equally to this work. approaches used to discriminate (likely) pathogenic from benign variants. ExAC and its successor gnomAD are currently the largest publicly available population-based reference datasets, providing the best variant frequency estimates. 2, 3 Cutoffs of low allele frequencies are often used, including 1%, 0.1%, or 0.01%. 4, 5 Recently, a gene-specific framework has been introduced, which accounts for disease prevalence, allelic and genetic heterogeneity, inheritance mode, and penetrance, resulting in cutoff values even below 0.01%. 6 Frequency cutoffs below 1%, however, may not be applicable to all clinical cases. Indeed, in apparently healthy population-based reference datasets low-allele-frequency cutoffs may not appropriately account for common genetic modifiers or for the considerable number of disease-affected individuals with atypical, late-onset, and/or unrecognized phenotypes. Moreover, recent reports of pseudo and true digenic inheritance indicate that the identification of a single disease-causing variant may be insufficient. [7] [8] [9] Neglecting these factors may result in the exclusion of clinically relevant sequence variants, leading to incomplete or even missed diagnoses. Here, we address these challenges by assessing the presence and frequency of a priori (likely) pathogenic variants in gnomAD as well as by showing hitherto unreported cases of digenic variants causing clinically relevant complex phenotypes.
| MATERIALS AND METHODS

| Evaluation of gnomAD
We compared the gnomAD-based relative frequencies of most likely pathogenic variants in the genes COL1A1, COL3A1, FBN1, FGFR2, JAG1, KMT2D, NSD1, SCN1A, TSC1, and TSC2 with the previously reported prevalence rates of respective autosomal-dominant disorders. In addition, we compared the carrier frequencies of selected known pathogenic variants causing pediatric and/or adult-onset disorders in the genes BRCA1, BRCA2, CFTR, GJB2, and HBB among ExAC, gnomAD, and currently appreciated estimates as described. 10 We hypothesized that such a comparison of observed and expected frequencies enables to assess whether or not (likely) pathogenic variants are overrepresented in gnomAD and, hence, gnomAD can be considered as representative for the general population (incl. individuals with genetic predisposition to adult-onset autosomal-dominant disorders).
| Detection of pathogenic variants in gnomAD
Variant call format files containing all sequence variants in gnomAD were downloaded from gnomAD.broadinstitute.com/downloads (r2.0.1; 123 136 exomes and 15 496 genomes; released 2017, genome build GRCh37/hg19) and parsed using LeftAlignAndTrimVariants contained in GATK 3.5. 11 Using VarSeq 2.0.1 (Golden Helix, Montana), the downloaded gnomAD sequence variants were annotated with several datasets and in silico tools (Supporting Information Table S1 ). To restrict the analysis to high-confidence calls, we excluded sequence variants with a non-PASS gnomAD filter, a 75-mer mappability <1, 12 or a position outside of the canonical transcript (Table " knownCanonical" in the track "UCSC Genes" from the UCSC Table browser; genome.ucsc.edu/ cgi-bin/hgTables) as well as indels with a length ≥50 bp. To assess the presence and frequency of (likely) pathogenic variants in gnomAD, we performed automated filtering using VarSeq as well as manual evaluation. Only genes exclusively associated with autosomal-dominant disorders (status "confirmed" in OMIM version 2018.5, omim.org) and with a DOMINO score ≥0.9 were selected. 13 To restrict our analyses to genes likely intolerant to loss-of-function (LOF) variants, only genes with a pLi score ≥0.9 and an "observed/expected" (o/e) metric 90% confidence interval upper bound <0.35 in gnomAD were further considered ( Figure 1 ). 2 Genes associated with disorders inherited in an autosomalrecessive or X-linked manner were not analyzed, because for the gnomAD dataset (r2.0.1) information on haplotype and sex is not (yet) available.
As prime examples, we focused on the genes FBN1 and FBN2, which cause the autosomal-dominant fibrillinopathies Marfan syndrome (MFS, OMIM #154700) and congenital contractural arachnodactyly (CCA, OMIM #121050), respectively. 14, 15 In addition to nonsense, frameshift, and splicing variants, FBN1 and FBN2 sequence variants disrupting the consensus calcium-binding sequence as well as disrupting or creating disulfide-bond-forming cysteines are known to be damaging and MFS/CCA-causing due to increased proteolytic degradation. [16] [17] [18] [19] Thus, such FBN1 and FBN2 sequence variants may be considered as a priori (likely) pathogenic, allowing the more elaborate gnomAD-based predisposition/prevalence assessment of fibrillinopathies.
We considered following sequence variants as most likely pathogenic in six (I-VI) categories ( Figure 1 ): (I) Nonsense and frameshift variants with or without expected nonsense-mediated mRNA decay, because both may cause disease but via separate mechanisms; 20, 21 (II) Single nucleotide variants located at the canonical splice sites (exonic ±1 bp, intronic ±1-2 bp) and in silico predicted to alter splicing (Supporting Information Table S1); (III) In-frame indels; 22, 23 (IV) Missense variants disrupting functionally critical amino acids in the calcium-binding epidermal growth factor domains of FBN1 and FBN2 such as disulfide-bond-forming cysteines as well as amino acids Asn, Asp, and Glu directly binding calcium (uniprot.org/uniprot/ P35555; uniprot.org/uniprot/P35556); [16] [17] [18] [19] Information Table S1 ).
Subsequently, categories I-II were applied to the entire gnomAD dataset, whereas categories III-VI were only applied to FBN1 (NM_000138.4, all exons) and FBN2 (NM_001999.3, CCA-mutationhotspot exons [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] . 24 Categories I-V were defined as sensu stricto selected, that is, sequence variants with clear evidence for pathogenicity, while category VI contains sensu lato selected sequence variants, that is, additional, potentially pathogenic variants requiring manual expert review and interpretation. To largely exclude false-positive results (ie, indeed non-pathogenic variants), we manually evaluated all gnomAD variants in categories I and II occurring above a low-frequency cutoff value of 0.01% or affecting genes with a total frequency of >1:2000. 5 Accordingly, variants were excluded if one of the following criteria was met: (a) ≥1 "benign" classifications in HGMD and/or ClinVar; (b) >10% allele frequency in any gnomAD subpopulation; (c) variant exclusively affects weakly expressed exon (<10% of the highest expressed exon in disease-relevant tissue according to gtexportal.org).
| Detection of FBN1/FBN2 dual variants in WGS data
WGS (PCR-free, 60× 150PE) of 500 individuals with rare, mainly cardiovascular or connective tissue disorders was performed as described. 25 FASTQ files were aligned using GENALICE MAP (Genalice, Nijkerk, The Netherlands). 26 Variant calling was performed using the Population Calling module of GENALICE MAP to simultaneously extract all FBN1 and FBN2 sequence variants in our database. 26 Using VarSeq, called sequence variants were annotated and filtered for individuals harboring (likely) pathogenic variants in both FBN1 and FBN2 (ie, dual variants). As a second interpretation platform, the artificial-intelligence-driven interpretation software Moon (Diploid, Leuven, Belgium) was used to independently detect FBN1/ FBN2 dual variants. For the confirmation of detected FBN1 and FBN2 variants and segregation analyses, Sanger sequencing of the corresponding region was performed as described. 27 Data on clinical phenotypes were collected from medical records and/or during physical examination by one of the authors (A.N., M.R., or B.S.). Written informed consent was obtained from patients and family members.
| ACMG/AMP classifications
Automated classifications using the American College of Medical
Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) published guidelines were obtained from InterVar v.201904/hg19. 28 For FBN1 variants disrupting disulfide-bondforming cysteines, the ACMG/AMP criterion PM1 (moderate evidence for pathogenicity) was manually adjusted to PS3 (strong evidence for pathogenicity) as previously suggested. 29 To avoid a bias caused by the ACMG/AMP criterion PM2 (moderate evidence for pathogenicity) fulfilled for variants absent from control populations, the automated classification was manually adapted by applying the criterion PM2 for extremely rare gnomAD variants as well (allele count ≤2). Likewise, for the two families with FBN1/FBN2 dual F I G U R E 1 Overview of used workflow. Categories I and II were applied to all genes associated with autosomal-dominant disorders in gnomAD, whereas categories III-VI were only applied to FBN1 and FBN2. *, † Data obtained from the Tables "wgEncodeCrgMapabilityAlign75mer" (*) and "knownCanonical" ( †) from the UCSC Karczewski et al. (2019) . 3 † † In FBN2 the prevalence calculation was limited to the CCA-mutationhotspot region (exons 23-34) for categories II-VI, while for category I (nonsense and frameshift) all exons were considered. ‡ ‡ Sequence variants predicted "damaging" or "deleterious" by all six used in silico prediction tools (FATHMM, FATHMM-MKL, MutationAssessor, MutationTaster, Polyphen2, SIFT; see also Supporting Information Table S1 ). CCA, congenital contractural arachnodactyly; gnomAD, Genome Aggregation Consortium; HGMD, Human Gene Mutation Database; indel, insertion/deletion; MFS, Marfan syndrome variants, segregation data (PP1) were manually adjusted in the classification.
| Statistical analysis
The upper and lower limits of the 95% confidence interval (CI) of a proportion were calculated using the online tool VassarStats with a correction for continuity (vassarstats.net/prop1.html) or the software GraphPad Prism 8 (GraphPad Software, California). Proportion of genetic predisposition and disease prevalence was calculated under the assumption that carrier individuals in gnomAD harbor no more than one (likely) pathogenic sequence variant in the considered gene(s).
| RESULTS
| Detection of pathogenic variants in gnomAD
Our comparison revealed that the evaluated carrier frequencies in the genes BRCA1, BRCA2, CFTR, GJB2, and HBB are not overrepresented in gnomAD (Supporting Information Table S2 ), confirming ExAC-based previous results. 10 In categories I and II (Figure 1 ), considering all gnomAD sequence variants in genes associated with autosomaldominant disorders (pLi ≥0.9, upper bound of the o/e metric 90% CI <0.35) we identified by software filtering and manual evaluation a total of 2653 a priori (likely) pathogenic variants in 253 genes. Ten of these genes are the major cause of disorders with previously reported prevalence but we found no clear evidence that gnomAD-based predisposition/prevalence rates are significantly higher than reported estimates (Supporting Information Figure S1 ). Per gene, 1 up to 130 gnomAD individuals harbor an a priori (likely) pathogenic variant with relative allele frequencies ranging from 1/246 272 (0.0004%) to 82/183 872 (0.0446%; ATXN7 c.2673delA; Supporting Information Figure S2 ), resulting in disease predisposition/prevalence estimates ranging from approximately 1:100 000 to approximately 110:100 000 not associating with pLi, o/e, or DOMINO values (Supporting   Information Table S3 , Supporting Information Figure S2 ). During manual evaluation, we detected 16 apparently a priori (likely) pathogenic variants, which we subsequently reclassified as (likely) non-pathogenic and thus excluded from the analysis. This reclassification was due to the less frequent allele being the reference allele in GRCH37/hg19 or to miscalled deletion/insertion variants or because the sequence variants are exclusively present in a weakly expressed exon (Supporting Information Table S4 and Table S5 ).
For the more elaborate predisposition/prevalence assessment of fibrillinopathies, we considered sequence variants of categories I-V (sensu stricto selected, Figure 1 Table S6 ).
Furthermore, from category VI (sensu lato selected, Figure 1 ) we added additional 880 FBN1 and 321 FBN2 missense variants that were in silico predicted to be (likely) deleterious, leading to a total of 947 and 360 potentially MFS-and CCA-causing variants, respectively. Accordingly, the gnomAD-based predisposition to MFS and CCA ranges from 4.8:10 000 (95% CI: 4-6:10 000) up to 68:10 000 (95% CI: 64-72:10 000) and 2.8:10 000 (95% CI: 2-4:10 000) up to 26:10 000 (95% CI: 23-29:10 000), respectively, depending whether sensu stricto and/or lato selected variants were considered (Table 1 ).
In gnomAD, the majority of the sensu stricto selected FBN1 and FBN2 sequence variants were detected in individuals aged ≥50 years and were rare, with a non-reference allele count of 1. However, the three most frequent sensu lato selected FBN1 variants, c.3890A>G (Table 1 ).
| Evaluation of HGMD and ClinVar entries
| Families with pathogenic variants in both FBN1 and FBN2
In our cohort of 500 genomes, screening for individuals harboring Table S7 ).
The female index patient of Family 1 (Ab2) ( Figure 3A) , who was referred with suspected CCA, harbors the heterozygous 
Reduced elbow extension (r / l) the large family of Ab2. 30 In addition, she harbors the heterozygous and marfanoid habitus. However, he showed no CCA-associated contractures (Table 2 ). Ac2, the father of Ac1, only harbors the FBN2 variant and presented with CCA-associated features such as finger contractures, MFS/CCA-overlapping features like arachnodactyly and high-arched palate, as well as high myopia (−12/−9 dpt), which is frequent in MFS and may also occur in CCA. 33, 34 Both Ac3, the mother of Ac1, and Ac4, the aunt of Ac1, only harbor the FBN1 variant and presented with mild MFS phenotypes and non-marfanoid habitus. The mother (Ac3) presented with MFS-associated elbow hyperextension, mild scoliosis, and no cardiovascular involvement ( First, although WGS is the most comprehensive HTS method offering advantages over targeted sequencing and WES, 25, 35 data interpretation remains a challenge. 12 Currently, there is no generally accepted gold standard software solution for variant interpretation comparable to BWA/GATK for alignment and variant calling. 11, 12 According to the ACMG/AMP guidelines, allele frequencies higher than expected for the disorder (criterion BS1) or reported >5% in population-based reference datasets (criterion BA1) count as strong or stand-alone evidence of benign impact of a variant. 1 Table S6 ), may occur rather frequently in one ethnicity (up to 0.12% allele frequency) and thus may be filtered out by using too low cutoff frequencies (ie, below 0.12%). Thus, filtering for sequence variants extremely rare or absent in population-based reference datasets is helpful to identify variants that should not be missed in a first step, while variants with an increased frequency should not be a priori disregarded without an appropriate consideration and literature review, especially in complex cases. 38 Additional rare exonic variants may pose challenges for interpretation, such as variants solely affecting weakly expressed exons or variants miscalled as two independent variants instead of a small insertion/deletion (Supporting Information Table S5 ). To avoid missed or incomplete diagnoses, there is an evident demand for more advanced filtering methods that may consider more elaborated algorithms, adapted cutoffs, paralogue annotations, 39 facial phenotyping algorithms, 40 or data sharing platforms. 41 Second, although current widely-used in silico tools and diseaseassociated databases are powerful, they are not without fault. In this study, not all in silico tools correctly classified all of the sensu stricto selected FBN1 and FBN2 variants. By individual use, these tools are therefore not capable of depicting all of the underlying diseasecausing mechanisms and, hence, we recommend combining multiple tools for the highest accuracy and the robust application of the ACMG/AMP criteria PP3 and BP4. 38 Moreover, several sequence variants classified as DM in HGMD or pathogenic in ClinVar were considered for category V but were excluded, because manual evaluation of the corresponding publication/entry revealed no convincing evidence of pathogenicity (ie, functional characterization or segregation analyses). Thus, even in curated datasets such as HGMD and ClinVar unreliable variant-disease associations might be present, which is why they need to be used with care and evaluated by experts. 42, 43 Third, the ACMG/AMP guidelines provide a framework for clinical variant classification. 1 To support implementation and increase inter- Information Table S6 ). 29 In addition, not only because gnomAD contains pathogenic variants but also because larger population datasets will emerge in the future, the criterion PM2 (moderate evidence for pathogenicity; fulfilled for variants absent from control populations) may require adjustment. As the application of population-based data is a major source of interlaboratory discordances, 38 increased number of population-based criteria (eg, 5 criteria instead of the existing 3, PM2, BA1, BS1), 46 or gene-specific frequency thresholds 6, 48 could help to appropriately implement the PM2 criterion. Indeed, in the absence of additional information, application of the PM2 criterion to extremely rare variants (allele count ≤2 in gnomAD) may lead to a reclassification, for example, from VUS (PVS1, PP3) to pathogenic (PVS1, PM2, PP3), representing a major caveat. Moreover, the ACMG/AMP guidelines were developed for highly-penetrant monogenic disorders, complicating their implementation in cases with (pseudo) digenic inheritance or with genetic modifiers (eg, because of the application of segregation data). As the ACMG/AMP guidelines are widely used, it is crucial to use classification tools prudently and to understand their limitations.
Depending on the used tool, the thresholds for several criteria may vary, leading to inconsistent or VUS classifications, which may be pivotal as the ACMG/AMP guidelines are frequently invoked for clinical decision support 47 and because VUS are not recommended to be reported to patients. 49 Fourth, as we detected 2653 a priori (likely) pathogenic gnomAD variants in genes associated with autosomal-dominant disorders, this dataset should be regarded as apparently, rather than completely, nonaffected. Nevertheless, our data suggest that (likely) pathogenic variants are not overrepresented and we found no clear evidence for considerable bias due to included disease-specific studies. Thus, gnomAD can be considered as an appropriate representation of the general population, thereby expanding the knowledge of pathogenic variants in ExAC to the much larger gnomAD database, 10 enabling (re-) estimation of the population prevalence of genomic disorders. In general, gnomAD genes of categories I-II ( Figure 1) with an increased number of (likely) pathogenic variants are not infrequently associated with highly-penetrant diseases with late onset and/or unapparent phenotype, which may occur in fibrillinopathies as well. Indeed, without appropriate imaging of the aorta, even old (≥50 years) carriers of pathogenic FBN1 and/or FBN2 variant(s) may be considered as apparently non-affected in gnomAD. Our gnomAD-based MFS predisposition rate of approximately 5:10 000 (FBN1 categories I-V) is higher than the previously reported prevalence of approximately 1-3:10 000, 33, 50 suggesting that highly-penetrant fibrillinopathies may be underdiagnosed, especially in mild cases. However, FBN1 mutations have been reported in other non-MFS disorders as well (cf. HGMD professional; portal.biobase-international.com). As for FBN2 we only considered the CCA-mutation-hotspot exons 23-34, the real predisposition to CCA might be even higher than our estimate of approximately 3:10 000. In contrast, some of the detected a priori (likely) pathogenic variants in gnomAD, although de facto (likely) pathogenic, might not lead to disease in certain resilient individuals. 51 Resilience may be due to protective genetic modifiers or absence of expression of the affected allele due to random monoallelic expression. 52, 53 Because we only considered PASS gnomAD variants (ie, genotype quality ≥20, allelic balance >0.2, and read depth ≥10) 2 with a mappability =1, 12 Table 2 ). The effect of dual variants appears synergistic for some clinical features, which has also been observed in an Fbn1/Fbn2 double knock-out mouse model. 54 For instance, severe kyphoscoliosis is exclusively present in the dual-variant carrier (Ac1) in The main limitation of our study is that for gnomAD phenotypic data of the participants is (yet) unavailable and thus the clinically relevant effect of detected variants can not be directly assessed. Furthermore, information whether multiple sequence variants are harbored by one individual is also unavailable in gnomAD, which would be necessary to assess digenic inheritance and genetic modifiers. Moreover, as we restricted our genome-scale analysis to categories I and II containing a priori (likely) pathogenic variants (nonsense, frameshift, and canonical splice sites), we potentially missed other (likely) pathogenic variants. We considered that for some genes (eg, GFAP, TGFBR1, TGFBR2) LOF is not (yet) established as a disease mechanism. Thus, to exclude such genes, we restricted our analyses to genes likely intolerant to LOF as predicted by both the pLi score and the o/e metric. 2, 3 Indeed, for all but one (ATXN7) of seven genes with (likely) pathogenic gnomAD-based allele frequencies >1:2000 (Supporting Information - Taken together, in the current genomics era using appropriate shortand/or long-read HTS platforms, the bottleneck on the path to accurate diagnosis is the interpretation of variants rather than the generation of data. 12 
